Teprenone

Summary

Teprenone (CHEMBL5314356) is a phase-3 clinical-stage unknown (ATC A02BX15); indicated across 4 conditions including gastroesophageal reflux disease and peptic ulcer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A02BX15
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314356
Name	Teprenone
Type	Unknown
Max phase	3
ATC	A02BX15

Also known as: E-0671, Geranylgeranylacetone, Selbex, Teprenona, Teprenone, TEPRENONE, Geranylgeranyl acetone, teprenone

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Type-1 angiotensin II receptor, Kappa-type opioid receptor, Nuclear receptor subfamily 1 group I member 2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	5.4	AC50	4000	nM	CHEMBL_ACT_25188378
AGTR1	5.06	AC50	8720	nM	CHEMBL_ACT_25177269

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948
peptic ulcer disease	3	MONDO:0004247	HP:0004398
duodenal ulcer	2	MONDO:0005412	EFO:0004607
heart failure	2	MONDO:0005252	EFO:0003144

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01190657	PHASE4	COMPLETED	Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
NCT01397448	PHASE2/PHASE3	COMPLETED	Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
NCT05672134	PHASE2	COMPLETED	Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).